(IQV) IQVIA Holdings - Ratings and Ratios
Clinical Research, Commercial Insights, Healthcare Intelligence
IQV EPS (Earnings per Share)
IQV Revenue
Description: IQV IQVIA Holdings
IQVIA Holdings Inc (NYSE:IQV) is a leading provider of clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries globally. The companys diverse portfolio of services is organized into three main segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
The Technology & Analytics Solutions segment is a key driver of IQVIAs growth, offering a range of cloud-based applications, real-world solutions, and strategic consulting services that enable life sciences companies to generate and disseminate evidence, inform healthcare decision-making, and improve patient outcomes. Notably, this segment provides granular insights into pharmaceutical sales, prescribing trends, and promotional activity across various channels, which can be a valuable asset for life sciences companies.
From a financial perspective, IQVIAs revenue growth, operating margins, and return on equity (RoE) are key performance indicators (KPIs) to monitor. With a RoE of 20.74%, IQVIA demonstrates a strong ability to generate profits from shareholder equity. Additionally, the companys debt-to-equity ratio and interest coverage ratio are important metrics to assess its financial health and leverage.
IQVIAs Research & Development Solutions segment is another significant contributor to the companys revenue, offering a range of services that support clinical trials, including project management, clinical monitoring, and laboratory services. The companys strategic collaboration with Sarah Cannon Research Institute is also a notable development, aimed at enhancing clinical trial processes and improving patient outcomes.
To further evaluate IQVIAs performance, its essential to analyze its revenue breakdown by segment, geographic region, and customer concentration. This can provide insights into the companys diversification, growth prospects, and potential risks. Moreover, monitoring IQVIAs cash flow generation, capital expenditures, and dividend yield can help investors assess the companys financial stability and returns.
IQV Stock Overview
| Market Cap in USD | 31,827m |
| Sub-Industry | Life Sciences Tools & Services |
| IPO / Inception | 2013-05-09 |
IQV Stock Ratings
| Growth Rating | -39.4% |
| Fundamental | 62.5% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -33.9% |
| Analyst Rating | 4.30 of 5 |
IQV Dividends
Currently no dividends paidIQV Growth Ratios
| Growth Correlation 3m | 71.5% |
| Growth Correlation 12m | -74.7% |
| Growth Correlation 5y | -18.9% |
| CAGR 5y | -3.01% |
| CAGR/Max DD 3y | -0.06 |
| CAGR/Mean DD 3y | -0.23 |
| Sharpe Ratio 12m | -0.78 |
| Alpha | -39.77 |
| Beta | 0.888 |
| Volatility | 32.93% |
| Current Volume | 946.2k |
| Average Volume 20d | 1194.1k |
| Stop Loss | 181.5 (-3.1%) |
| Signal | -0.92 |
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income (1.24b TTM) > 0 and > 6% of Revenue (6% = 942.0m TTM) |
| FCFTA 0.07 (>2.0%) and ΔFCFTA 0.10pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -7.82% (prev -6.59%; Δ -1.23pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.09 (>3.0%) and CFO 2.62b > Net Income 1.24b (YES >=105%, WARN >=100%) |
| Net Debt (13.66b) to EBITDA (3.35b) ratio: 4.08 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.84 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (173.2m) change vs 12m ago -6.02% (target <= -2.0% for YES) |
| Gross Margin 34.25% (prev 35.10%; Δ -0.85pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 57.06% (prev 57.41%; Δ -0.35pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 3.24 (EBITDA TTM 3.35b / Interest Expense TTM 688.0m) >= 6 (WARN >= 3) |
Altman Z'' 1.27
| (A) -0.04 = (Total Current Assets 6.34b - Total Current Liabilities 7.57b) / Total Assets 28.63b |
| (B) 0.23 = Retained Earnings (Balance) 6.58b / Total Assets 28.63b |
| (C) 0.08 = EBIT TTM 2.23b / Avg Total Assets 27.52b |
| (D) 0.25 = Book Value of Equity 5.70b / Total Liabilities 22.85b |
| Total Rating: 1.27 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 62.47
| 1. Piotroski 4.50pt = -0.50 |
| 2. FCF Yield 4.44% = 2.22 |
| 3. FCF Margin 12.80% = 3.20 |
| 4. Debt/Equity 2.68 = -0.28 |
| 5. Debt/Ebitda 4.63 = -2.50 |
| 6. ROIC - WACC 2.36% = 2.95 |
| 7. RoE 19.96% = 1.66 |
| 8. Rev. Trend 87.22% = 4.36 |
| 9. Rev. CAGR 4.47% = 0.56 |
| 10. EPS Trend 27.93% = 0.70 |
| 11. EPS CAGR 1.00% = 0.10 |
What is the price of IQV shares?
Over the past week, the price has changed by -0.25%, over one month by -1.15%, over three months by +17.56% and over the past year by -21.79%.
Is IQVIA Holdings a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of IQV is around 164.49 USD . This means that IQV is currently overvalued and has a potential downside of -12.14%.
Is IQV a buy, sell or hold?
- Strong Buy: 14
- Buy: 2
- Hold: 7
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the IQV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 215.9 | 15.3% |
| Analysts Target Price | 215.9 | 15.3% |
| ValueRay Target Price | 180.3 | -3.7% |
Last update: 2025-09-15 04:38
IQV Fundamental Data Overview
CCE Cash And Equivalents = 2.04b USD (last quarter)
P/E Trailing = 27.0941
P/E Forward = 14.2857
P/S = 2.0272
P/B = 5.5084
P/EG = 0.9656
Beta = 1.324
Revenue TTM = 15.70b USD
EBIT TTM = 2.23b USD
EBITDA TTM = 3.35b USD
Long Term Debt = 14.18b USD (from longTermDebt, last quarter)
Short Term Debt = 1.31b USD (from shortTermDebt, last quarter)
Debt = 15.49b USD (Calculated: Short Term 1.31b + Long Term 14.18b)
Net Debt = 13.66b USD (from netDebt column, last quarter)
Enterprise Value = 45.28b USD (31.83b + Debt 15.49b - CCE 2.04b)
Interest Coverage Ratio = 3.24 (Ebit TTM 2.23b / Interest Expense TTM 688.0m)
FCF Yield = 4.44% (FCF TTM 2.01b / Enterprise Value 45.28b)
FCF Margin = 12.80% (FCF TTM 2.01b / Revenue TTM 15.70b)
Net Margin = 7.88% (Net Income TTM 1.24b / Revenue TTM 15.70b)
Gross Margin = 34.25% ((Revenue TTM 15.70b - Cost of Revenue TTM 10.32b) / Revenue TTM)
Tobins Q-Ratio = 7.94 (Enterprise Value 45.28b / Book Value Of Equity 5.70b)
Interest Expense / Debt = 1.17% (Interest Expense 182.0m / Debt 15.49b)
Taxrate = 17.74% (296.0m / 1.67b)
NOPAT = 1.83b (EBIT 2.23b * (1 - 17.74%))
Current Ratio = 0.84 (Total Current Assets 6.34b / Total Current Liabilities 7.57b)
Debt / Equity = 2.68 (Debt 15.49b / last Quarter total Stockholder Equity 5.78b)
Debt / EBITDA = 4.63 (Net Debt 13.66b / EBITDA 3.35b)
Debt / FCF = 7.71 (Debt 15.49b / FCF TTM 2.01b)
Total Stockholder Equity = 6.20b (last 4 quarters mean)
RoA = 4.32% (Net Income 1.24b, Total Assets 28.63b )
RoE = 19.96% (Net Income TTM 1.24b / Total Stockholder Equity 6.20b)
RoCE = 10.93% (Ebit 2.23b / (Equity 6.20b + L.T.Debt 14.18b))
RoIC = 8.93% (NOPAT 1.83b / Invested Capital 20.53b)
WACC = 6.57% (E(31.83b)/V(47.32b) * Re(9.29%)) + (D(15.49b)/V(47.32b) * Rd(1.17%) * (1-Tc(0.18)))
Shares Correlation 3-Years: -96.92 | Cagr: -0.81%
Discount Rate = 9.29% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 74.10% ; FCFE base≈1.94b ; Y1≈1.96b ; Y5≈2.15b
Fair Price DCF = 178.8 (DCF Value 30.40b / Shares Outstanding 170.0m; 5y FCF grow 1.13% → 3.0% )
Revenue Correlation: 87.22 | Revenue CAGR: 4.47%
Rev Growth-of-Growth: 0.00
EPS Correlation: 27.93 | EPS CAGR: 1.00%
EPS Growth-of-Growth: -33.10
Additional Sources for IQV Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle